Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial
European Respiratory Journal · 2025
DOI: 10.1183/13993003.02443-2024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Barry J Plant und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Cork, Ireland b.plant@ucc.ie. Hauptthemen laut MEDLINE: Cystic Fibrosis, Anti-Bacterial Agents, Microbiota, Pseudomonas Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust, NIDDK NIH HHS, Seventh Framework Programme.
Abstract (Originalsprache)
Background
This study explores the effectiveness and safety of microbiome-directed antimicrobial therapy versus usual antimicrobial therapy in adult cystic fibrosis pulmonary exacerbations.
Methods
A multicentre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 to August 2017). All participants were chronically colonised with Pseudomonas aeruginosa and were randomised 1:1 into two study arms. The “usual therapy” group received 2 weeks of intravenous ceftazidime 3 g thrice daily (for allergies: aztreonam 2 g thrice daily) and tobramycin 5–10 mg·kg −1 once daily. The “microbiome-directed” group received the same usual therapy plus an additional antibiotic with greatest presumed activity against the second, third and fourth most abundant genera present in the sputum microbiome, selected by a consensus expert treatment panel. The primary outcome was change in percentage of predicted forced expiratory volume in 1 s (ppFEV 1 ) at 14 days post initiation of antibiotics. Secondary outcomes examined ppFEV 1 at 7 days, 28 days and 3 months; time to next exacerbation; symptom burden at 7 days; health-related quality of life (HRQoL) at 28 days; and number of exacerbations and i.v. antibiotic days at 12 months.
Results
149 participants had an eligible exacerbation (usual therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV 1 at day 14 (−1.1%, 95% CI −3.9–1.7%; p=0.46), or ppFEV 1 measured at other time points, or for time to next exacerbation (microbiome-directed versus usual therapy hazard ratio 0.91, 95% CI 0.60–1.38; p=0.66). The microbiome-directed group trended to have more i.v. days (median 42 days versus 28 days; p=0.08) and more subsequent exacerbations (median three versus two; p=0.044) the following year. There were no appreciable differences in symptom burden; however, HRQoL subscores were consistently worse in the microbiome-directed group (−4.3 points versus usual therapy, 95% CI −8.3–−0.3 points; p=0.033).
Conclusion
The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Cork, Ireland b.plant@ucc.ie.
- The HRB funded Clinical Research Facility, University College Cork, Cork, Ireland.
- Department of Medicine, University College Cork, Cork, Ireland.
- School of Pharmacy, Queens University Belfast, Belfast, UK.
- Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, University College Cork, Cork, Ireland.
- Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.
ORCID-Profile: Barry J Plant, Gisli G Einarsson, Kevin F Deasy, Darren Dahly, Peter J Barry, Christopher H Goss, Isabelle Fajac, Tamara Vagg, Isabelle Durieu, Evelyn Flanagan, Clémence Martin, Pierre-Régis Burgel, Charles S Haworth, R Andres Floto, Damian G Downey, Lieven J Dupont, Andrew M Jones, J Stuart Elborn, Marcus A Mall, Michael M Tunney
Förderung
- Wellcome Trust
- NIDDK NIH HHS
- Seventh Framework Programme
Zitieren
APA
Plant, B. J., Einarsson, G. G., Deasy, K. F., Dahly, D., Singh, P. K., Barry, P. J., Goss, C. H., Fajac, I., Vagg, T., Durieu, I., Flanagan, E., O'Callaghan, G., Martin, C., Burgel, P. R., Haworth, C. S., Floto, R. A., Downey, D. G., Dupont, L. J., Jones, A. M., …, & Tunney, M. M. (2025). Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial. European Respiratory Journal. https://doi.org/10.1183/13993003.02443-2024
Vancouver
Plant BJ, Einarsson GG, Deasy KF, Dahly D, Singh PK, Barry PJ, et al. Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial. European Respiratory Journal. 2025. doi:10.1183/13993003.02443-2024
BibTeX
@article{Plant2025,
author = {Plant, Barry J and Einarsson, Gisli G and Deasy, Kevin F and Dahly, Darren and Singh, Pradeep K and Barry, Peter J and Goss, Christopher H and Fajac, Isabelle and Vagg, Tamara and Durieu, Isabelle and Flanagan, Evelyn and O'Callaghan, Grace and Martin, Clémence and Burgel, Pierre-Régis and Haworth, Charles S and Floto, R Andres and Downey, Damian G and Dupont, Lieven J and Jones, Andrew M and Elborn, J Stuart and Eustace, Joseph A and Mall, Marcus A and Tunney, Michael M},
title = {Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.02443-2024}
}
EUVIMED